{"title":"晚期肝纤维化（而非 MASLD）与生物老化加速有关：一项基于人群的研究。","authors":"Chengcheng Tong, Yufeng Xue, Wei Wang, Xi Chen","doi":"10.1186/s12889-024-20808-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The process of biological aging in patients diagnosed with chronic liver disease remains unclear.</p><p><strong>Aim: </strong>The current study aims to investigate if there is an accelerated biological aging process in participants with advanced fibrosis (AF) and metabolic dysfunction-associated steatotic liver disease (MASLD).</p><p><strong>Methods: </strong>Data from the 2017-2018 NHANES cycle were analyzed. AF was determined based on the values of liver stiffness measurement (LSM) and MASLD was defined according to new consensus nomenclature. Klemera-Doubal method biological age (KDM bioage) and Phenotypic age (Phenoage) were adopted to quantify biological age. Phenoage advancement (Phenoage_advance) and KDM advancement (KDM_advance) were generated as the difference between the calculated biological age and chronological age, and a positive residual was regarded as an indicator of accelerated biological aging.</p><p><strong>Results: </strong>A total of 3974 participants was enrolled. The weight mean KDM_advance and phenoage_advance in AF group was 4.22 years (95%CI: 2.96-5.49 years) and 2.61 years (95%CI: 1.80-3.41 years), while in MASLD group was 0.37 years (95%CI: -0.28-1.03 years) and 0.04 years (95%CI: -0.64-0.72 years), respectively. Multivariate linear regression analysis showed that participants with AF had older KDM_advance and phenoage_advance compared with those without AF (1.50 years (95%CI: 0.23-2.77 years), P = 0.02; 1.00 years (95%CI: 0.18-1.82 years), P = 0.02; respectively), in models adjusting demographic characteristics, socioeconomic status, lifestyle factors, and comorbidities. No significant association was found between MASLD and KDM_advance and phenoage_advance.</p><p><strong>Conclusions: </strong>AF, not MASLD, was independently associated with accelerated biological aging in adults from a US representative sample.</p>","PeriodicalId":9039,"journal":{"name":"BMC Public Health","volume":"24 1","pages":"3293"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study.\",\"authors\":\"Chengcheng Tong, Yufeng Xue, Wei Wang, Xi Chen\",\"doi\":\"10.1186/s12889-024-20808-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The process of biological aging in patients diagnosed with chronic liver disease remains unclear.</p><p><strong>Aim: </strong>The current study aims to investigate if there is an accelerated biological aging process in participants with advanced fibrosis (AF) and metabolic dysfunction-associated steatotic liver disease (MASLD).</p><p><strong>Methods: </strong>Data from the 2017-2018 NHANES cycle were analyzed. AF was determined based on the values of liver stiffness measurement (LSM) and MASLD was defined according to new consensus nomenclature. Klemera-Doubal method biological age (KDM bioage) and Phenotypic age (Phenoage) were adopted to quantify biological age. Phenoage advancement (Phenoage_advance) and KDM advancement (KDM_advance) were generated as the difference between the calculated biological age and chronological age, and a positive residual was regarded as an indicator of accelerated biological aging.</p><p><strong>Results: </strong>A total of 3974 participants was enrolled. The weight mean KDM_advance and phenoage_advance in AF group was 4.22 years (95%CI: 2.96-5.49 years) and 2.61 years (95%CI: 1.80-3.41 years), while in MASLD group was 0.37 years (95%CI: -0.28-1.03 years) and 0.04 years (95%CI: -0.64-0.72 years), respectively. Multivariate linear regression analysis showed that participants with AF had older KDM_advance and phenoage_advance compared with those without AF (1.50 years (95%CI: 0.23-2.77 years), P = 0.02; 1.00 years (95%CI: 0.18-1.82 years), P = 0.02; respectively), in models adjusting demographic characteristics, socioeconomic status, lifestyle factors, and comorbidities. No significant association was found between MASLD and KDM_advance and phenoage_advance.</p><p><strong>Conclusions: </strong>AF, not MASLD, was independently associated with accelerated biological aging in adults from a US representative sample.</p>\",\"PeriodicalId\":9039,\"journal\":{\"name\":\"BMC Public Health\",\"volume\":\"24 1\",\"pages\":\"3293\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Public Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12889-024-20808-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12889-024-20808-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study.
Background: The process of biological aging in patients diagnosed with chronic liver disease remains unclear.
Aim: The current study aims to investigate if there is an accelerated biological aging process in participants with advanced fibrosis (AF) and metabolic dysfunction-associated steatotic liver disease (MASLD).
Methods: Data from the 2017-2018 NHANES cycle were analyzed. AF was determined based on the values of liver stiffness measurement (LSM) and MASLD was defined according to new consensus nomenclature. Klemera-Doubal method biological age (KDM bioage) and Phenotypic age (Phenoage) were adopted to quantify biological age. Phenoage advancement (Phenoage_advance) and KDM advancement (KDM_advance) were generated as the difference between the calculated biological age and chronological age, and a positive residual was regarded as an indicator of accelerated biological aging.
Results: A total of 3974 participants was enrolled. The weight mean KDM_advance and phenoage_advance in AF group was 4.22 years (95%CI: 2.96-5.49 years) and 2.61 years (95%CI: 1.80-3.41 years), while in MASLD group was 0.37 years (95%CI: -0.28-1.03 years) and 0.04 years (95%CI: -0.64-0.72 years), respectively. Multivariate linear regression analysis showed that participants with AF had older KDM_advance and phenoage_advance compared with those without AF (1.50 years (95%CI: 0.23-2.77 years), P = 0.02; 1.00 years (95%CI: 0.18-1.82 years), P = 0.02; respectively), in models adjusting demographic characteristics, socioeconomic status, lifestyle factors, and comorbidities. No significant association was found between MASLD and KDM_advance and phenoage_advance.
Conclusions: AF, not MASLD, was independently associated with accelerated biological aging in adults from a US representative sample.
期刊介绍：
BMC Public Health is an open access, peer-reviewed journal that considers articles on the epidemiology of disease and the understanding of all aspects of public health. The journal has a special focus on the social determinants of health, the environmental, behavioral, and occupational correlates of health and disease, and the impact of health policies, practices and interventions on the community.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
